BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.40% Shs Outstand155.93M Perf Week1.15%
Market Cap15.16B Forward P/E- EPS next Y-1.98 Insider Trans-20.79% Shs Float147.14M Perf Month6.25%
Income-126.20M PEG- EPS next Q-0.60 Inst Own- Short Float2.64% Perf Quarter18.08%
Sales667.10M P/S22.73 EPS this Y-34.70% Inst Trans0.18% Short Ratio3.11 Perf Half Y59.35%
Book/sh10.26 P/B9.48 EPS next Y-90.40% ROA-5.40% Target Price107.06 Perf Year42.41%
Cash/sh4.27 P/C22.76 EPS next 5Y25.00% ROE-8.70% 52W Range55.04 - 100.50 Perf YTD7.58%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-3.23% Beta0.96
Dividend %- Quick Ratio4.20 Sales past 5Y13.10% Gross Margin83.70% 52W Low76.69% ATR3.51
Employees1341 Current Ratio5.20 Sales Q/Q29.10% Oper. Margin-23.30% RSI (14)55.19 Volatility3.51% 3.69%
OptionableYes Debt/Eq0.44 EPS Q/Q113.20% Profit Margin-18.90% Rel Volume1.03 Prev Close99.58
ShortableYes LT Debt/Eq0.44 EarningsFeb 24 AMC Payout- Avg Volume1.25M Price97.25
Recom1.80 SMA201.94% SMA506.13% SMA20034.60% Volume1,288,839 Change-2.34%
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Sep-18-13Downgrade Stifel Buy → Hold
Jul-26-13Reiterated Stifel Buy $67 → $70
Apr-03-13Reiterated Barclays Overweight $54 → $70
Mar-20-13Reiterated RBC Capital Mkts Outperform $58 → $64
Mar-20-13Reiterated Deutsche Bank Hold $45 → $59
Feb-22-13Reiterated RBC Capital Mkts Outperform $55 → $58
Feb-01-13Reiterated UBS Buy $53 → $67
Jan-22-13Upgrade Stifel Nicolaus Hold → Buy $67
Nov-06-12Reiterated Barclays Overweight $46 → $54
Nov-06-12Downgrade Brean Capital Buy → Hold
Sep-28-12Reiterated Summer Street Research Buy $45 → $52
Aug-27-12Downgrade Deutsche Bank Buy → Hold $40 → $45
Jan-28-15 06:25PM  Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog Zacks
Jan-27-15 07:30AM  Rare feat: BioMarin rewrites playbook for small-market drug approvals at American City Business Journals
06:00AM  Jim Cramer's Top Stock Picks: BMRN HSY KMB at TheStreet
Jan-26-15 08:22PM  Jim Cramer's 'Mad Money' Recap: 8 Ways to Tell a Healthy Market From a Sick One at TheStreet
Jan-24-15 06:00AM  'Mad Money' Lightning Round: Constellation Brands the New King in Town at TheStreet
Jan-23-15 07:36PM  Lightning Round: These stocks bottomed last week at CNBC
04:55PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S EDGAR Online
08:00AM  BioMarin Announces Underwriters' Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Jan-22-15 06:00PM  BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks
07:56AM  Money. Biotech. More Money. Biotech. Lots of Money. Biotech. Yahoo Finance Contributors
12:40AM  BioMarin Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jan-21-15 04:01PM  BioMarin Announces Public Offering of Common Stock GlobeNewswire
06:25AM  State Of The Union Lights Up Biotech Benzinga
05:00AM  Losing to win, in pro basketball and business at Fortune
Jan-16-15 07:00PM  Cramer Executive Cut: Transportation & biotech CNBC
03:34PM  Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical Benzinga
06:01AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition EDGAR Online
06:00AM  Jim Cramer's Top Stock Picks: NVAX TGT BMRN RCPT at TheStreet
Jan-15-15 08:01PM  Jim Cramer's 'Mad Money' Recap: 5 Reasons Why You Must Buy American Stocks at TheStreet
06:42PM  Cramer's top biotech has enormous value creation at CNBC
06:35PM  BioMarin CEO: Vimizim launch better than anticipated CNBC
01:10PM  Biotech Rivalry Gets Nasty in Mudslinging Battle Over Trial Data at Bloomberg
08:00AM  BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period GlobeNewswire
Jan-14-15 05:10PM  BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog Zacks
07:08AM  UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data Benzinga
Jan-12-15 02:38PM  BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation at TheStreet
01:45PM  BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a Form of Batten Disease GlobeNewswire
09:47AM  Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year at TheStreet
Jan-09-15 03:42PM  Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily
Jan-08-15 04:44PM  Thursday's Market Recap Yahoo Finance Blogs
Jan-07-15 04:15PM  BioMarin Announces Planned Changes to Board of Directors Leadership Structure GlobeNewswire
Jan-06-15 08:00AM  BioMarin to Present at the J.P. Morgan Healthcare Conference GlobeNewswire
Dec-29-14 08:00AM  BioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome GlobeNewswire
Dec-24-14 01:15PM  BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa GlobeNewswire
Dec-23-14 05:24PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online -5.94%
04:11PM  BioMarin CEO Sees Big Future For Prosensa Drug at Investor's Business Daily
Dec-22-14 08:23AM  J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 at TheStreet
Dec-12-14 12:40PM  PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
Dec-10-14 12:32PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement EDGAR Online
08:01AM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome GlobeNewswire
08:00AM  FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B) GlobeNewswire
Dec-09-14 08:00AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York GlobeNewswire
Dec-07-14 04:00PM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome GlobeNewswire
Dec-05-14 06:00AM  Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet
Dec-03-14 05:24PM  Rare disease biotech deal CNBC
08:00AM  BioMarin to Host Analyst and Investor Day on December 10th in New York GlobeNewswire
06:00AM  Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES at TheStreet
Dec-02-14 08:21PM  Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners at TheStreet
07:07PM  Cramer Remix: The best stocks to own now at CNBC
06:12PM  Cramer: Cut the line on bottom fishing! at CNBC
05:18PM  RBC's biotech picks: CELG, BMRN & VRTX CNBC
05:00PM  7 Biotech stocks to buy now CNBC
04:53AM  Transforming Biotech Coal to Gold: A Look At Puma, BioMarin and Cellceutix Company Spotlight
Dec-01-14 08:05AM  KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors PR Newswire
Nov-28-14 08:34AM  The Zacks Analyst Blog Highlights: BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex Zacks
Nov-26-14 04:47PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-24-14 05:24PM  It was another slow, low volume, lackluster trading session Yahoo Finance Blogs
04:49PM  US STOCKS-S&P 500 ticks up to record on central bank bets Reuters
04:37PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
03:58PM  Barbarian At The Gate: Biomarin Pharmaceutical (BMRN) at TheStreet
03:19PM  US STOCKS-Wall St up on central bank bets, deals support Reuters
12:34PM  US STOCKS-Wall St hits new records, but telecom weighs on Dow Reuters
12:20PM  BioMarin's Prosensa Buy: A 'Courageous' Acquisition? at Barrons.com
11:18AM  US STOCKS-Wall St hits new records, boosted by cyclicals Reuters
10:50AM  BioMarin to Pay Up to $840 Million for Prosensa at The Wall Street Journal
10:24AM  In Risky Bet, BioMarin Acquires Prosensa for as Much as $840 Million at BusinessWeek
10:22AM  BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
10:04AM  US STOCKS-Wall St surges to new records, boosted by cyclicals Reuters
09:19AM  Stock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily
08:52AM  US STOCKS-Futures point to higher open on merger activity Reuters
08:14AM  US STOCKS-Futures rise, boosted by merger activity Reuters
07:59AM  Early Movers: UTX, VZ, TSLA, LGA, RNA & more at CNBC
07:35AM  BioMarin Pharma offers about $680M for Prosensa AP
07:14AM  US STOCKS-Futures higher, building on recent gains Reuters
06:58AM  November 24 Premarket Briefing: 10 Things You Should Know TheStreet
06:45AM  BioMarin Buys Muscular Dystrophy Treatment Developer Prosensa at Bloomberg
06:34AM  BioMarin Expands Reach By Buying Prosensa for Up to $840 Million at TheStreet
06:34AM  BioMarin Acquires Prosensa in Deal Valued Up to $840 Million at TheStreet
06:24AM  BioMarin to buy Prosensa in $840 mln deal Reuters
06:00AM  BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio GlobeNewswire
Nov-21-14 10:03AM  Fighting kids' cancer, one voucher at a time at CNBC
06:00AM  How to get cancer drugs to kids: A mother's take at CNBC
Nov-19-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
Nov-14-14 02:30PM  Street Talk: HOG, LULU, BMRN, MDVN & TRS CNBC -5.77%
Nov-12-14 04:30PM  Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? Zacks
Nov-10-14 04:28PM  Major averages start the week where they left offhigher Yahoo Finance Blogs
08:45AM  Top Analyst Upgrades and Downgrades: BioMarin, BP, Genworth, Petrobras, Target and More at 24/7 Wall St.
Nov-04-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08:00AM  Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference GlobeNewswire
Nov-03-14 04:31PM  It was a lackluster trading session for U.S. equities Yahoo Finance Blogs
02:30PM  Street Talk: Downgrade for Deans CNBC
09:55AM  Cramer's Stop Trading: Stratasys & BioMarin CNBC
Oct-30-14 08:08PM  10-Q for BioMarin Pharmaceutical, Inc. Company Spotlight
Oct-29-14 07:55AM  Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? Zacks
Oct-28-14 03:10PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-27-14 02:12AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% Zacks
Oct-24-14 01:00PM  BioMarin Q3 Loss Narrower than Expected, View Raised Zacks +8.03%
Oct-23-14 04:57PM  BioMarin beats 3Q profit forecasts AP
04:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM